

Supplementary Table S4. Characteristics and Safety Outcomes of Studies Included in the Safety Analysis

#	Study	Population, N (intralipid/control)	Comparator	Adverse events	
				Intralipid group	Control group
RCT (n = 4)					
1	Peivandi 2022	Women with ≥2 RIF, N = 80 (40/40)	No treatment (normal saline)	No adverse events	No adverse events
2	Dogra 2021 (abstract)	Women with RIF, N = 14	No treatment (normal saline)	No adverse events	NR
3	Gamaledin 2018 (abstract)	Women with unexplained RIF, N = 97	No treatment (normal saline)	Adverse events (2 cases): congenital external ear malformation (n = 2)	NR
4	Meng 2016	Women with ≥2 RIF, N = 154 (76/78)	IVIG	No adverse events	Adverse events (7 cases): mild fever (n = 5), headache (n = 2)
NRCS (n = 2)					
1	Rogenhofer 2022	Women with ≥3 RPL, N = 12 (10/4)	No treatment	No adverse events	NR
2	Kumar 2016 (abstract)	Women with unexplained primary RPL, N = 50	Low molecular weight heparin (LMWH)	Obstetric complications (3 cases): pre-eclampsia (n = 1), intrauterine growth restriction (n = 1), placental abruption (n = 1); no serious adverse events	No serious adverse events
Case study and case series (n = 5)					
1	Anya 2024	Woman with RPL (5 episodes); 41-year-old woman; 2 prior myomectomies	—	No adverse events	
2	Manning 2019 (abstract)	Women with RIF, N = 35	—	No adverse events	
3	Ehrlich 2016 (abstract)	History of RPL or IF, N = 64; indication for treatment: elevated uterine or peripheral NK cell levels	—	Adverse events (2 cases): facial flushing and pre-seizure symptoms (n = 1); asymmetric fetal intrauterine growth restriction (n = 1)	
4	Kaul 2014 (abstract)	Women with RIF, N = 76; ≥5 prior implantation failures; elevated NK cell activity	—	No adverse events	
5	Holschbach 2014 (abstract)	Women with RPL or RIF, N = 14; elevated NK cell levels; excluded for soy allergy	—	No adverse events (allergy or adverse reaction)	

ART: Assisted Reproductive Technology; BMI: Body Mass Index; ES: Endometrial Scratching; ET: Embryo Transfer; GnRH: Gonadotropin-Releasing Hormone; ICSI: Intracytoplasmic Sperm Injection; IVF: In Vitro Fertilization; IVIG: Intravenous Immunoglobulin; IVIL: Intravenous Intralipid; NR: not reported; RCT: Randomized Controlled Trial; RIF: Recurrent Implantation Failure; RPL: Recurrent Pregnancy Loss; NRCS: non-randomized comparative study